So the current guidelines, despite the absence of level one evidence, continue to recommend continuing bone modifying agents beyond the first two years. Our study really shows that it’s likely safe for select patients to be able to give these agents perhaps less frequently at least. And so I think participants that enrolled on the study were pre-selected patients that were likely not having disease progression and doing well, people that weren’t actively having recurrent skeletal events...
So the current guidelines, despite the absence of level one evidence, continue to recommend continuing bone modifying agents beyond the first two years. Our study really shows that it’s likely safe for select patients to be able to give these agents perhaps less frequently at least. And so I think participants that enrolled on the study were pre-selected patients that were likely not having disease progression and doing well, people that weren’t actively having recurrent skeletal events. And so those are the subgroups of patients that should be considered for de-escalation.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
